3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
8
Resectable Pancreatic Carcinoma
1
Resectable Pancreatic Cancer
1
Rectal Neoplasms
1
Pancreatic Ductal Adenocarcinoma
1
Advanced Pancreatic Cancer
1
Adenocarcinoma of the Pancreas
1
Adenocarcinoma
1
Interventions
Oxaliplatin
30
Gemcitabine
28
Fluorouracil
27
Capecitabine
22
Leucovorin
19
pembrolizumab
15
130-nm albumin-bound paclitaxel
13
Irinotecan
12
Cisplatin
11
Bevacizumab
11
Albumin-Bound Paclitaxel
11
Paclitaxel
10
Ramucirumab
8
Radiotherapy
8
Docetaxel
8
Nivolumab
7
trastuzumab deruxtecan
6
Cyclophosphamide
6
Taxes
5
Drug Therapy
5
durvalumab
4
Trastuzumab
4
Metformin
4
zolbetuximab
3
spartalizumab
3
folfirinox
3
cemiplimab
3
XELOX
3
Surgical Procedures, Operative
3
Sorafenib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma
×
paricalcitol
×
Gastrointestinal
×
Clear all
NCT03415854
2026-05-12
NABPLAGEMD
HonorHealth Research Institute
Phase 2
Completed
34 enrolled
11 charts